Short Interest in Autolus Therapeutics plc (NASDAQ:AUTL) Increases By 12.4%

Autolus Therapeutics plc (NASDAQ:AUTL) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totalling 8,630,000 shares, a growth of 12.4% from the December 15th total of 7,680,000 shares. Based on an average daily volume of 1,830,000 shares, the days-to-cover ratio is currently 4.7 days.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. The Goldman Sachs Group raised Autolus Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the stock from $7.00 to $7.60 in a research note on Monday, November 18th. Needham & Company LLC reissued a “buy” rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Monday, January 13th. Finally, Redburn Atlantic raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price target for the company in a research report on Friday, November 15th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $10.40.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP boosted its stake in Autolus Therapeutics by 35.4% in the 3rd quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock valued at $87,919,000 after buying an additional 6,330,392 shares in the last quarter. FMR LLC increased its position in shares of Autolus Therapeutics by 44.6% during the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company’s stock worth $64,519,000 after purchasing an additional 5,478,706 shares in the last quarter. Erste Asset Management GmbH bought a new position in Autolus Therapeutics during the 3rd quarter valued at about $708,000. Renaissance Technologies LLC lifted its holdings in Autolus Therapeutics by 253.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,145,056 shares of the company’s stock valued at $3,985,000 after purchasing an additional 821,156 shares during the last quarter. Finally, GSA Capital Partners LLP acquired a new position in Autolus Therapeutics in the third quarter valued at about $1,082,000. 72.83% of the stock is owned by institutional investors.

Autolus Therapeutics Stock Performance

Shares of Autolus Therapeutics stock opened at $2.22 on Monday. Autolus Therapeutics has a 52 week low of $2.07 and a 52 week high of $7.37. The company’s 50-day moving average price is $2.70 and its two-hundred day moving average price is $3.56. The stock has a market cap of $590.72 million, a PE ratio of -1.83 and a beta of 2.05.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same quarter in the previous year, the business earned ($0.26) earnings per share. On average, equities analysts predict that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.